Cerus Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cerus stock.
View analyst ratings for Cerus or view top-rated stocks.

Wall Street analysts have given Cerus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cerus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cerus is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Cerus.

Cerus Co. (NASDAQ:CERS) posted its quarterly earnings results on Tuesday, May, 4th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.01. The biotechnology company earned $23.38 million during the quarter, compared to analyst estimates of $21.50 million. Cerus had a negative trailing twelve-month return on equity of 57.92% and a negative net margin of 62.93%.
View Cerus' earnings history.

Cerus' stock was trading at $4.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CERS shares have increased by 23.7% and is now trading at $5.89.
View which stocks have been most impacted by COVID-19.

Cerus updated its FY 2021 earnings guidance on Tuesday, May, 25th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $110 million-$114 million, compared to the consensus revenue estimate of $130.95 million.

1 equities research analysts have issued 12 month price targets for Cerus' shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Cerus' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 52.8% from the stock's current price.
View analysts' price targets for Cerus or view top-rated stocks among Wall Street analysts.

15 employees have rated Cerus CEO William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among Cerus' employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Cerus include Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), STAAR Surgical (STAA), Quidel (QDEL), Neogen (NEOG), ICU Medical (ICUI), Merit Medical Systems (MMSI), Haemonetics (HAE), Atrion (ATRI), Meridian Bioscience (VIVO), Antares Pharma (ATRS), OraSure Technologies (OSUR) and Anika Therapeutics (ANIK).
View all of CERS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Cerus' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (14.92%), Nikko Asset Management Americas Inc. (7.84%), Sumitomo Mitsui Trust Holdings Inc. (7.77%), BlackRock Inc. (7.41%), Primecap Management Co. CA (5.95%) and Wasatch Advisors Inc. (3.52%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Timothy L Moore, Vivek K Jayaraman and William Mariner Greenman.
View institutional ownership trends for Cerus.

CERS stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, D. E. Shaw & Co. Inc., Sepio Capital LP, Morgan Stanley, Millennium Management LLC, Primecap Management Co. CA, Cubist Systematic Strategies LLC, and SG Americas Securities LLC. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Vivek K Jayaraman, and William Mariner Greenman.
View insider buying and selling activity for Cerus or view top insider-selling stocks.

CERS stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Kennedy Capital Management Inc., Paradigm Capital Management Inc. NY, Pier Capital LLC, BlackRock Inc., and Geode Capital Management LLC.
View insider buying and selling activity for Cerus or or view top insider-buying stocks.

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CERS stock can currently be purchased for approximately $5.89.

Cerus has a market capitalization of $1.01 billion and generates $91.92 million in revenue each year. The biotechnology company earns $-59,860,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

Cerus employs 254 workers across the globe.

The official website for Cerus is www.cerus.com.

Cerus is headquartered at 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520.

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at (925) 288-6000 or via email at [email protected]